ProCE Banner Events

Share

Therapeutic Advances in R/R DLBCL: Improving Outcomes with Novel Approaches to Targeted Therapy [Open Registration]

Register now for this CME/ABIM MOC-certified interactive workshop series on therapeutic advances and novel approaches to targeted therapy in relapsed/refractory DLBCL!

US Physicians: maximum of 1.00 Medical Knowledge MOC point(s)

Physicians: maximum of 1.00 AMA PRA Category 1 Credit™

This event has expired. No longer available for credits.

Credits Available

1.0

Who Should Attend

The intended audience for this educational initiative includes community hematologists, oncologists, and other clinicians involved in the care of patients with DLBCL.

Time and location

Wednesday, November 29, 2023

7:30 AM - 8:30 AM Central Time (CT)

Virtual

CCO Simulcast | Host Group NE
Lincoln, Nebraska

Faculty
Priyanka Pophali, MD

Assistant Professor
Division of Hematology, Medical Oncology, and Palliative Care
Department of Medicine
University of Wisconsin, Carbone Cancer Center
UW Health
Madison, Wisconsin

Agenda

Welcome and Introductions
Advances in the Treatment of R/R DLBCL
•    NCCN clinical treatment guidelines
•    Data supporting recently approved targeted therapy options
•    Expert recommendations on selecting between treatment options
Emerging Options for Personalized Patient Care
•    Potential therapeutic targets and new treatment modalities for DLBCL
•    Targeted therapies in late-stage development
•    Potential role of new therapies in the treatment paradigm
•    Important of clinical trial enrollment
Audience Q&A

Location

Venue Name

CCO Simulcast | Host Group NE

Address

CCO Simulcast | Host Group NE
Lincoln, Nebraska

CME/CE Info

Goal Statement
The goal of this program is to improve the knowledge, confidence, and competence of learners in selecting individualized treatments for patients with relapsed or refractory diffuse large B-cell lymphomas.

Target Audience
The intended audience for this educational initiative includes community hematologists, oncologists, and other clinicians involved in the care of patients with DLBCL.

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Outline the most recent treatment guidelines for relapsed/refractory DLBCL, including the role of novel targeted therapies in the treatment paradigm
  • Evaluate novel targeted therapies currently in development for treatment of relapsed/refractory DLBCL
  • Develop personalized treatment plans for patients with relapsed/refractory DLBCL based on clinical trial data and guideline and expert recommendations

 

Accreditation

Relevant Financial Relationships Disclosures:

USF Health and Rockpointe adhere to the Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to influence content have disclosed to USF Health any financial relationship with an ineligible organization. Prior to the activity, USF Health will disclose and mitigate all relevant financial relationships that relate to the content of the activity.

Physician Continuing Medical Education

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through a joint providership of USF Health and Rockpointe. USF Health is accredited by the ACCME to provide continuing medical education for physicians.

USF Health designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

For information about accreditation of this activity, please email: cpdsupport@usf.edu 

ABIM MOC RECOGNITION STATEMENT


Successful completion of the CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is USF Health’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

To receive CME credit and/or MOC points, you MUST pass the post-test and complete the evaluation. For ABIM MOC points, your information will be shared with the ABIM through USF Health’s ACCME Program and Activity Reporting System (PARS). Please allow 6-8 weeks for your MOC points to appear on your ABIM records.

Participants will earn MOC Points equivalent to the amount of CME credits claimed for the activity. USF Health will submit within 60 days the Participant’s MOC Points. No MOC certificates will be provided. Participants with questions regarding their Points, should contact USF Health at cpdsupport@usf.edu.

Acknowledgement

Jointly provided by USF Health and Rockpointe.

This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc.

Contact Information

Contact Clinical Care Options

For customer support please click here.

Mailing Address:

 

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Additional Information

There are no fees required to participate in this activity.

Americans With Disabilities Act 
Event staff will be glad to assist you with any special needs (eg, physical, dietary). Please contact customer support prior to the live event.